PUBLIC STRATEGIES WASHINGTON, INC.

Lobbying for NOVO NORDISK INC. · Pharmaceutical company

Filing 3rd Quarter - Report

3rd Quarter (July 1 - Sep 30) 2025 · District of Columbia · House · Senate · $30,000.00 income · posted Oct 20, 2025

Lobbying activity 1

Medicare/Medicaid

Issues related to the coverage of obesity therapeutics

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.

Report a problem